AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06683755
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT06684873
Drug: AK112 Injection
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 injection plus chemotherapy was administered to all eligible patients
Trial: NCT06684522
Drug: Upadacitinib 15 MG
RxNorm normalized name: upadacitinib 15 MG
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib 15mg daily
Trial: NCT05540665
Drug: Daxdilimab
RxNorm normalized name: Daxdilimab
DrugBank: Daxdilimab (DB16391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734
Trial: NCT05540665
Drug: Placebo (Normal Saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously as two injections for each dose.
Trial: NCT04868045
Drug: Thyrotropin Releasing Hormone (TRH)
RxNorm normalized name: thyrotropin-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.
Trial: NCT05344833
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
Trial: NCT05344833
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
Trial: NCT05915013
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine
Trial: NCT05915013
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral perampanel (6 mg)
Trial: NCT05588557
Drug: Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee).
Trial: NCT05588557
Drug: ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee).
Trial: NCT05028751
Drug: Lanraplenib
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally via tablets
Trial: NCT05028751
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally via tablets
Trial: NCT06040268
Drug: Advair HFA
RxNorm normalized name: Advair HFA
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
Trial: NCT05000684
Drug: JS004 in combination with toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks
Trial: NCT04232306
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine liposome injectable suspension
Trial: NCT04232306
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl surgical-site incision infiltration
Trial: NCT06542549
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
Trial: NCT04340700
Drug: THC or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
Trial: NCT05064488
Drug: Evobrutinib
RxNorm normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
Trial: NCT05064488
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Trial: NCT05064488
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Trial: NCT05064488
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
Trial: NCT05832216
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
Trial: NCT06218303
Drug: Hiltonol®
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
Trial: NCT05320627
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will receive Edoxaban tablet once a day for 12 weeks
Trial: NCT00119600
Drug: AMG 114
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06771596
Drug: Nimotuzumab Injection
RxNorm normalized name: inotuzumab ozogamicin Injection
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab is a highly humanized monoclonal antibody of IgG1 type, with a humanization rate of 95%. It is highly specific, has a long half - life, and shows high selectivity and a high degree of humanization. It can specifically block the epidermal growth factor receptor (EGFR) signaling pathway and mediate immune effects such as antibody - dependent cell - mediated cytotoxicity (ADCC) and complement - dependent cytotoxicity (CDC). It also promotes the endocytosis and degradation of EGFR, thereby inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells, reversing the malignant biological behavior of tumor cells at the molecular level.
Trial: NCT06447220
Drug: washed microbiota transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prepared microbiota suspension was infused into the patients' gut.
Trial: NCT06274216
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU of vitamin D3 orally every day for 12 weeks
Trial: NCT06274216
Drug: Vitamin E 400
RxNorm normalized name: vitamin E 400 UNT
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg of vitamin E orally every day for 12 weeks
Trial: NCT04901754
Drug: Camrelizumab Plus Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD.
Trial: NCT00002227
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002227
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002227
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04129515
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
Trial: NCT05967117
Drug: Iohexol (320mgI/mL) with 120kVp
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Trial: NCT06428019
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral: Tablet
Trial: NCT06428019
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral: Tablet
Trial: NCT06428019
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05010005
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 20mg BID
Trial: NCT05010005
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Duvelisib 25mg, 50mg, or 75mg BID
Trial: NCT05505292
Drug: Lifitegrast 5% Ophthalmic Solution
RxNorm normalized name: Lifitegrast 5% Ophthalmic Solution
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed twice a day for 8 weeks
Trial: NCT06635889
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
Trial: NCT06771492
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days
Trial: NCT06770296
Drug: Pyrotinib low dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Trial: NCT06770296
Drug: Pyrotinib normal dose group
RxNorm normalized name: Streptococcus viridans group
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Trial: NCT06300528
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
Trial: NCT05967117
Drug: Iohexol (320mgI/mL) with 100kVp
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Trial: NCT05967117
Drug: Iohexol (270mgI/mL) with 100kVp
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Trial: NCT05967117
Drug: Iohexol (240mgI/mL) with 100kVp
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Trial: NCT06494007
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Diltiazem monotherapy group received 6.66 mL of IV sodium chloride 0.9% (NaCl) prior to receiving IV weight-adjusted diltiazem.
Trial: NCT06494007
Drug: 90 mg of calcium
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Diltiazem with 90 mg calcium group received 3.33 mL of IV calcium chloride (CaCl2, 90 mg) and 3.33 mL of IV NaCl 0.9% as pretreatment over 5-10 min prior to receiving IV diltiazem.
Trial: NCT06494007
Drug: 180 mg Calcium
RxNorm normalized name: simethicone 180 MG
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Diltiazem with 180 mg calcium group received 6.66 mL of IV CaCl2 (180 mg) as pretreatment prior to receiving IV diltiazem.
Trial: NCT06138964
Drug: siSPARC + siLR4A microneedle patches
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siSPARC + siLR4A microneedle patch
Trial: NCT06138964
Drug: siSPARC microneedle patch
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siSPARC microneedle patch
Trial: NCT05949944
Drug: Linperlisib in combination with CHOP
RxNorm normalized name: miconazole
DrugBank: Linperlisib (DB17235)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
Trial: NCT05232006
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib, once daily
Trial: NCT00099645
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06024733
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient recieve propofol for induction and sevoflurane for maintenance
Trial: NCT06024733
Drug: Target Controlled Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target controlled infusion of propofol
Trial: NCT06024733
Drug: Target Controlled Infusion and lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
Trial: NCT06274905
Drug: EMLA
RxNorm normalized name: EMLA
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream
Trial: NCT06274905
Drug: Ethyl chloride
RxNorm normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride
Trial: NCT05862285
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Trial: NCT05862285
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Trial: NCT05862285
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Trial: NCT05155709
Drug: siremadlin
RxNorm normalized name: Siremadlin
DrugBank: Siremadlin (DB16331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
Trial: NCT05155709
Drug: venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
Trial: NCT05155709
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
Trial: NCT06385990
Drug: UTD1
RxNorm normalized name: Uridine Triacetate
DrugBank: Uridine triacetate (DB09144)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
Trial: NCT04830644
Drug: Iguratimod
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod orally twice a day
Trial: NCT04968054
Drug: Arm I (Propofol)
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
Trial: NCT05856227
Drug: Ceftobiprole medocaril
RxNorm normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
Trial: NCT04968054
Drug: Arm II (Remimazolam)
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
Trial: NCT04768985
Drug: Treatment A: Acalabrutinib tablet
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
Trial: NCT04768985
Drug: Treatment B: Acalabrutinib capsule
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
Trial: NCT06066580
Drug: Sevasemten
RxNorm normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevasemten is administered orally once per day
Trial: NCT06772480
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months
Trial: NCT00001115
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000626
Drug: Vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no